Send us Feedback

Gentium SpA (GENT)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
Gentium (GENT) Misses Q1 EPS Views; Revs Light
StreetInsider.com  May 17  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Gentium+%28GENT%29+Misses+Q1+EPS+Views%3B+Revs+Light/7449579.html for the full story.
Gentium (GENT) Gets Day 180 List from EMA for Defibrotide MAA
StreetInsider.com  May 4  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Gentium+%28GENT%29+Gets+Day+180+List+from+EMA+for+Defibrotide++MAA/7403438.html for the full story.
Gentium Receives Day 180 List of Outstanding Issues From the CHMP for Defibrotide MAA
Benzinga  May 4  Comment 
Gentium Appoints PharmaSwiss, S.A. as Exclusive Distributor of Defibrotide in Central and Eastern European Countries
Globe Newswire  May 2  Comment 
VILLA GUARDIA (COMO), Italy, May 2, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) today announced the appointment of PharmaSwiss S.A., a division of Valeant Pharmaceuticals International, Inc., as the exclusive distributor of Defibrotide in
UPDATE: Brean Murray Carret Initiates Coverage on Gentium S.p.A.
Benzinga  Apr 4  Comment 
According to a research report released this morning, Brean Murray Carret has initiated Gentium S.p.A. (NASDAQ: GENT) with a Buy rating and $16 PT. In the report, Brean Murray Carret said, “We are initiating coverage of Gentium S.p.A. (GENT)...
Gentium Hosts Symposium on Defibrotide at EBMT Annual Meeting
Globe Newswire  Apr 2  Comment 
VILLA GUARDIA (COMO), Italy, April 2, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that the Company's lead product, Defibrotide, was the subject of a symposium, "How can defibrotide tackle two critical early
Gentium Appoints Dr. Carin Heringa as Senior Vice President and Scientific Director
Globe Newswire  Mar 6  Comment 
VILLA GUARDIA, Italy, March 6, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that Dr. Carin Heringa, Head of Global Medical Affairs of Gentium, has been newly appointed as the Company's Senior Vice President
Gentium (GENT) Reports Publication of Encouraging Defibrotide Results on VOD in Certain Patients
StreetInsider.com  Feb 27  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Gentium+%28GENT%29+Reports+Publication+of+Encouraging+Defibrotide+Results+on+VOD+in+Certain+Patients/7214534.html for the full story.
The Lancet Publishes Results from Gentium's Phase III Defibrotide Trial for the Prevention of VOD in Paediatric Patients
Globe Newswire  Feb 27  Comment 
Gentium Responds to the EMA's Day 120 List of Questions for Defibrotide MAA
Globe Newswire  Feb 21  Comment 
VILLA GUARDIA, Italy, Feb. 21, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that it has submitted its response to the Day 120 List of Questions (the "LoQs") issued by the European Medicines Agency's ("EMA")
Gentium (GENT) Appoints Exclusive Defibrotide Distributor for Several Nordic Markets
StreetInsider.com  Jan 9  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Gentium+%28GENT%29+Appoints+Exclusive+Defibrotide+Distributor+for+Several+Nordic+Markets/7066397.html for the full story.
Gentium Appoints Swedish Orphan Biovitrum AB as Exclusive Distributor of Defibrotide in Nordic and Baltic Territories
Globe Newswire  Jan 9  Comment 
Gentium Provides Update on MAA Process for Defibrotide in Europe
Benzinga  Dec 29  Comment 
Gentium S.p.A. (Nasdaq: GENT) today provided an update on the European Marketing Authorization Application for Defibrotide to treat and prevent hepatic veno-occlusive disease in adults and children undergoing haematopoietic stem-cell...
Gentium S.p.A. (GENT) to Submit Response to LoQs from EMA Over Defibrotide MAA
StreetInsider.com  Dec 29  Comment 




more ▼WIKI ANALYSIS
 The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.


 




References

Retrieved from "http://www.wikinvest.com/stock/Gentium_SpA_(GENT)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki